ALX Oncology Unveils Promising Results from Aspen-05 Study: Evorpacept in Combination with Azacitidine and Venetoclax Shows Tolerability and Early Efficacy in Acute Myeloid Leukemia Patients

ALX Oncology Announces Initial Data from ASPEN-05 Study of Evorpacept in Combination with Azacitidine and Venetoclax Antileukemic Activity Demonstrated ALX Oncology recently announced the initial data from the ASPEN-05 study, showcasing promising antileukemic activity in patients with both relapsed/refractory and newly diagnosed Acute Myeloid Leukemia (AML). No Observations of Cytopenias or Maximum Tolerated Dose The…

Read More

Keros Therapeutics Unveils Exciting Clinical and Preclinical Data at the 64th American Society of Hematology Annual Meeting

Keros Therapeutics Presents Clinical Data from its KER-050 and KER-… Keros Therapeutics Hosts Conference Call and Webcast Keros Therapeutics will be hosting a conference call and webcast today, December 12, 2022, at 4:01 p.m. ET. The event will provide an opportunity for investors, analysts, and the general public to learn more about the latest clinical…

Read More

Attention Shareholders: Kaskela Law LLC Launches Investigation into Chegg Inc. (NYSE: CHGG) – Take Action Now for Long-Term CHGG Investors!

The Investigation of Chegg, Inc. by Kaskela Law LLC Introduction On December 12, 2022, Kaskela Law LLC announced that it is investigating Chegg, Inc. (“Chegg” or the “Company”) (NYSE: CHGG) on behalf of the Company’s long-term stockholders. The investigation stems from a recent securities fraud complaint filed against Chegg on behalf of investors who purchased…

Read More

Breaking News: Pasithea Therapeutics Reaches Comprehensive Settlement Agreement with The Camac Group

Pasithea Therapeutics Announces Comprehensive Settlement Agreement with the Camac Group MIAMI BEACH, Fla., Dec. 12, 2022 (GLOBE NEWSWIRE) Pasithea Therapeutics Corp. (Nasdaq: KTTA) Pasithea Therapeutics Corp., a biotechnology company focused on the discovery, research and development of innovative treatments for central nervous system (CNS) disorders, today announced that it has reached a comprehensive Settlement and…

Read More

Get Ready to Conquer the Stock Market: A Fun and Relatable Look at DAX 40 & Dow Jones Weekly Analysis (12th-16th December)

Market movers: European stock exchanges closed the week mixed and with much uncertainty as they await this week’s central bank decisions. In addition, the publication in the early afternoon of producer prices in the United States (on a monthly basis at +0.3%, expectations for +0.2%) also raised fears for continued tightening of interest rates. Following…

Read More

Discover the Latest on TransUnion: Important Shareholder Notice – Contact Robbins LLP for Details on Our Investigation!

TransUnion (TRU) Shareholder Notice: Contact Robbins LLP for Information About our Investigation San Diego, Dec. 12, 2022 (GLOBE NEWSWIRE) – Shareholder rights law firm Robbins LLP is currently conducting an investigation into TransUnion (NYSE: TRU) to determine whether certain officers and directors of the company have violated securities laws and breached fiduciary duties to shareholders….

Read More

Important Deadline Approaching for Voyager Digital Holdings Investors: Seek Counsel Now, Advises Trusted National Trial Counsel Rosen in Securities Class Action for VGX Losses

The Impact of Voyager Digital Holdings Investor Losses Introduction Recently, Rosen Law Firm has issued a reminder to purchasers of Voyager Earn Accounts and VGX tokens about potential losses incurred between January 1, 2020 and November 9, 2022. This news has caused a stir among investors and raised questions about the security and reliability of…

Read More

Unleashing the Power of Science: Senti Bio’s Exciting Preclinical Findings at the ASH Annual Meeting and Investor Event!

Senti Bio Highlights Preclinical Data from Logic-Gated Gene Circuit CAR-NK Cell Therapy SENTI-202 at ASH Annual Meeting… Exciting Advances in Cell Therapy Have you heard the latest buzz from the ASH Annual Meeting? Senti Bio presented groundbreaking preclinical data on their innovative off-the-shelf CAR-NK cell therapy candidate, SENTI-202. This therapy is engineered with a logic-gated…

Read More